Overview

The 2025 Pulmonary Hypertension Summit will provide you with an overview of the practical issues in the diagnosis, evaluation, and management of patients with pulmonary hypertension. Expert speakers will present the most recent advances in the context of challenges faced by physicians and other health care providers caring for these patients. Faculty will present on advances in diagnosis and risk stratification, emerging therapeutics, management of populations with concomitant disease, and technological innovations. Take advantage of this unique opportunity, either in-person or via live stream.

Learning Objectives

• Demonstrate optimal procedures for right heart catheterization, echocardiography, and cardiopulmonary exercise tests.
• Detail the evidence base and clinical use of risk assessment tools and treatment algorithms for diagnosing, classifying, and treating pulmonary arterial hypertension.
• Critically review the pharmacologic profile, efficacy and side effect data, and clinical indications for sotatercept and discuss its role in treating pulmonary arterial hypertension.
• Summarize research advances in the pathobiology, diagnosis, and treatment of pulmonary hypertension as well as clinical trial design.
• Describe the diagnosis and management of concomitant conditions that occur in patients with pulmonary hypertension, including chronic lung disease, heart failure, right ventricular dysfunction, connective tissue disease, and thromboembolic pulmonary hypertension.

Target Audience

The Summit is directed to physicians, physician’s assistants, nurse practitioners, nurses, and pharmacists with an interest in pulmonary hypertension.

Accreditation

Cleveland Clinic Center for Continuing Education designates this live activity for a maximum of 14.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.